RBC Capital Markets Reiterates Sector Perform Rating for Valeant...

RBC Capital Markets Reiterates Sector Perform Rating for Valeant...


's stock had its "sector perform" rating reissued by equities researchers at RBC Capital Markets in a research note issued to investors on Monday. They currently have a $36.00 target price on the specialty pharmaceutical company's stock.



from Biotech News